Use: Labeled indications
- INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.
Full indications and usage US FDA label
INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.
They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella /Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and S treptococci, including Streptococcus pneumoniae.
Contraindications
CONTRAINDICATIONS MAXITROL ® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. MAXITROL is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION One to two drops in the conjunctival sac(s). In severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides. In mild disease, drops may be used up to four to six times daily. Not more than 20 mL should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness in pediatric patients below the age of 2 years have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Ophthalmic & otic suspension: 1 mg/3. 5 mg/6000 IU, 1 mg/3.5 mg/6000 IU
- Ophthalmic & otic solution: 1 mg/3.5 mg/6000 IU
Registered products in the Philippines
11 products registered with the Food and Drug Administration (FDA) Philippines list Dexamethasone + Neomycin + Polymyxin-b-sulfate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products11
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Dexa-NPDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg/ 3.5 mg/6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap | Rx | Egyptian International Pharmaceutical Industries Co.Egypt | Preventia Healthcare Inc.Importer: Ambica International Corporation | DRP-7734-07 | Mar 16, 2028 | |
DexatrolDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg/3.5 mg/6000 I.U Ophthalmic SuspensionBox of 1 LDPE plastic bottle x 5 mL with HDPE tamper proof cap | Rx | Egyptian International Pharmaceutical Industries Co.Egypt | Pharmabiz Solutions, Inc.Importer: Ambica International Corporation | DRP-7734 | Mar 16, 2028 | |
DexneomyxDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg/3. 5 mg/6000 IU Ophthalmic & Otic SuspensionLDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co.Egypt | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-7734-12 | Mar 16, 2028 | |
DuodexDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg /3. 5 mg /6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap | Rx | Egyptian International Pharmaceutical Industries Co.Egypt | Sensorycare Pharma Co.Importer: Ambica International Corporation | DRP-7734-13 | Mar 16, 2028 | |
GoxetrolDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg/3.5 mg/6000 I.U. Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap | Rx | Egyptian International Pharmaceutical Industries Co.Egypt | Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation | DRP-7734-05 | Mar 16, 2028 | |
IpodexDexamethasone + Neomycin (as Sulfate) + Polymyxin-B-Sulfate | 1 mg/ 3.5 mg / 6000 I.U. Ophthalmic and Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | I-Senz Medical Inc.Importer: Ambica International Corporation | DRP-7734-03 | Mar 16, 2028 | |
NeosporexDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg/3.5 mg/6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap | Rx | Egyptian International Pharmaceutical Industries Co.Egypt | Ophtha Pharma Traders Inc.Importer: Ambica International Corporation | DRP-7734-06 | Mar 16, 2028 | |
Polymix-DDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg / 3.5 mg / 6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap | Rx | Egyptian International Pharmaceutical Industries Co.,Egypt | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-7734-10 | Mar 16, 2028 | |
PonedaDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg / 3.5mg/6000 IU Ophthalmic & Otic SolutionLDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-7734-08 | Mar 16, 2028 | |
RaypondexDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg / 3.5 mg/ 6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap | Rx | Egyptian International Pharmaceutical Industries Co.Egypt | RCL Ophthalmic SurgicalsImporter: Ambica International Corporation | DRP-7734-09 | Mar 16, 2028 | |
RetapidecxDexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate | 1 mg/ 3.5 mg/ 6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap | Rx | Egyptian International Pharmaceutical Industries Co.Egypt | Reta DrugImporter: Ambica International Corporation | DRP-7734-11 | Mar 16, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS NOT FOR INJECTION. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections. Acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication.
Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. If this product is used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients.
Steroids should be used with caution in the presence of glaucoma. IOP should be checked frequently. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. MAXITROL ® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.
Products containing neomycin sulfate may cause cutaneous sensitization. Sensitivity to topically administered aminoglycosides, such as neomycin, may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions.
If hypersensitivity develops during use of the product, treatment should be discontinued. Cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available. Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations.
The reactions due to the corticosteroid component are: elevation of IOP with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. Corticosteroid-containing preparations have also been reported to cause perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following use of steroids.
Additional adverse reactions identified from post marketing use include ulcerative keratitis, headache, and Stevens-Johnson syndrome. The following additional adverse reactions have been reported with dexamethasone use: Cushing’s syndrome and adrenal suppression may occur after use of dexamethasone in excess of the listed dosing instructions in predisposed patients, including children and patients treated with CYP3A4 inhibitors.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose. In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, cleft palate. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc.
There are no adequate or well-controlled studies in pregnant women. However, prolonged or repeated corticoid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation. MAXITROL ® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.
Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Systemically administered corticosteroids appear in human milk, could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when MAXITROL ® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is administered to a nursing woman.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.
When a decision to administer both a corticosteroid and an antimicrobial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered, plus assured compatibility of ingredients when both types of drugs are in the same formulation and, particularly, that the correct volume of drug is delivered and retained. The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Maxitrol · Harrow Eye, LLC [US FDA-approved label, version 5, October 24, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ecfb954f-5554-0ad2-e053-2995a90a7516
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .